Parexat

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Parexat

What is Parexat?

Parexat is a medication that belongs to a class of drugs known as selective serotonin reuptake inhibitors (SSRIs). It is primarily utilized in the management of various mental health conditions characterized by persistent changes in mood, anxiety, or behavior.

Therapeutic Purpose

The medication is designed to assist in stabilizing emotional states and reducing the intensity of symptoms associated with specific psychological disorders. It is most commonly used for:

  • Major Depressive Disorder: Addressing symptoms of clinical depression, such as persistent sadness, loss of interest, and low energy.
  • Anxiety Disorders: Managing conditions including generalized anxiety disorder (GAD), social anxiety disorder, and panic disorder.
  • Obsessive-Compulsive Disorder (OCD): Helping to reduce intrusive thoughts and repetitive behaviors.
  • Post-Traumatic Stress Disorder (PTSD): Assisting in the management of symptoms following a traumatic event.

Mechanism of Action

Parexat works by influencing the chemical balance within the brain. Specifically, it targets a neurotransmitter called serotonin, which plays a critical role in regulating mood, sleep, and appetite. Under normal conditions, serotonin is released by nerve cells and then reabsorbed.

In individuals experiencing depression or anxiety, the availability of serotonin may be imbalanced. Parexat inhibits the reabsorption (reuptake) of serotonin into the neurons. By blocking this process, the medication increases the amount of active serotonin available in the synaptic gap between nerve cells, which helps to improve the transmission of signals and ultimately leads to a more balanced emotional state.

Regulatory References

  1. MedlinePlus Reference

What side effects are possible with Parexat?

Possible side effects and safety information

The official safety profile for Parexat, containing the active substance Paroxetine, classifies documented adverse reactions by their frequency and the body system affected, consistent with regulatory standards (e.g., EMA and FDA). The most frequently reported adverse reaction is Nausea, which is categorized as Very Common (ge 1/10). Other frequently listed effects, categorized as Common, include somnolence, insomnia, decreased appetite, sweating, dizziness, dry mouth, tremor, and certain forms of sexual dysfunction.

Safety Classifications and Constraints

The regulatory documentation groups adverse reactions into categories such as Gastrointestinal Disorders, Nervous System Disorders, and Psychiatric Disorders. Clinically significant events are highlighted within the safety labeling, including the documented risk of Serotonin Syndrome, Acute Glaucoma, and the potential for Hyponatraemia (low sodium levels), particularly noted in older adults.

Population and Time-Related Safety

Official constraints define specific safety considerations for patient groups. Constraints exist for individuals with renal or hepatic impairment, where drug exposure may be increased. For pediatric and adolescent patients, the risk of suicidal-related behaviors and hostility is specifically documented. Time-related patterns acknowledge that certain effects, such as Akathisia (restlessness), are most likely to appear within the first few weeks of treatment, and the risk for suicidal ideation may be heightened during the initial months of therapy or following dose changes.

Overdose and Emergency Response

Overdose and When to Seek Help

All suspected or confirmed Parexat (Paroxetine) overdosage events constitute a medical emergency requiring immediate attention. The regulatory profile notes that while a wide margin of safety is generally evident, severe outcomes are possible.

Overdose manifestations, as documented by official sources, often include signs of Central Nervous System (CNS) and cardiovascular hyperstimulation. Symptoms can range from agitation, tremor, headache, somnolence, and vomiting to more serious findings such as tachycardia (fast heart rate) and involuntary muscle contractions.

A major concern explicitly highlighted in regulatory labeling is the potential for Serotonin Syndrome, a life-threatening complication, and the risk of severe events like seizures and coma. Overdose severity is noted to be increased when Parexat is combined with alcohol or other serotonergic agents.

Treatment for overdose is officially described as purely symptomatic and supportive, as no specific antidote is known. Due to the risk of cardiac and neurological effects (e.g., QTc interval prolongation), continuous clinical monitoring is required.

Immediate Action Required: You must seek immediate medical attention for all suspected overdoses. Contact emergency services immediately if the affected individual has collapsed, is having a seizure, cannot be awakened, or has trouble breathing.

Therapeutic Uses of Parexat

Generally, the medication is commonly used to address conditions characterized by periods of heightened symptoms, which may create noticeable functional strain. It is applied across several therapeutic domains where additional symptomatic support is needed.

Parexat is used to manage psychiatric and mood conditions, including Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Panic Disorder (PD), Social Anxiety Disorder (SAD), Generalized Anxiety Disorder (GAD), Posttraumatic Stress Disorder (PTSD), and Premenstrual Dysphoric Disorder (PMDD). It also provides supportive relief in addressing symptoms related to heightened physiological activity, such as vasomotor symptoms (hot flashes and night sweats) associated with menopause. The medication supports the patient's efforts to maintain functional stability and emotional equilibrium during symptomatic periods, contributing to easing the overall symptom load.


Quick Fact: Symptom Support Therapeutic Target
Relief for Chronic Distress Pervasive sadness, hopelessness, and excessive, chronic worry.
Relief for Acute Episodes Sudden panic attacks, intrusive thoughts, and ritualized compulsions.
Relief for Physical Burden Moderate to severe vasomotor symptoms (physical discomfort related to systemic imbalance).

The core therapeutic benefit is focused on moderating symptom intensity in situations involving emotional dysregulation, fear, or cyclical distress, helping to maintain a sense of stability when symptoms are more noticeable.

Regulatory References

  1. NIH MedlinePlus overview of paroxetine's uses

Eligibility and Restrictions for Use

Eligibility and Contraindications

Parexat (Paroxetine) is officially approved for use only in adults (age 18 and older). Its eligibility profile is strictly defined by regulatory bodies, outlining populations who must not use the medicine and those who require restricted use.

Absolute Contraindications

Population/Condition Regulatory Status
Concomitant use with MAOIs (including linezolid, methylene blue) Prohibited (risk of Serotonin Syndrome)
Concomitant use with Pimozide or Thioridazine Prohibited (risk of cardiac events)
Known Hypersensitivity to Paroxetine or ingredients Prohibited

Age and Physiological Restrictions

Population/Condition Eligibility Rule
Children and Adolescents (Under 18) Not approved for psychiatric use; safety and efficacy not established
Older Adults (Age 65 and older) Restricted use due to higher plasma concentrations
Severe Renal or Hepatic Impairment Restricted use to the lower end of the dosage range
Pregnancy (especially first trimester) Conditional use; documented risk of fetal harm (e.g., cardiac malformations)
Lactation (Breastfeeding) Conditional use; passes into breast milk

What should I know about interactions with other medicines?

Interactions with other medicines and products

The use of Parexat (paroxetine) requires careful consideration of its interactions with other medications, primarily due to its effects on serotonin levels and its ability to inhibit a key liver enzyme.

Contraindicated Combinations

Concomitant use of paroxetine with Monoamine Oxidase Inhibitors (MAOIs), including the antibiotics linezolid and intravenous methylene blue, is contraindicated. A 14-day washout period must elapse between stopping an MAOI and starting paroxetine, or vice-versa, to avoid the risk of Serotonin Syndrome.

Paroxetine is also contraindicated with thioridazine and pimozide. Paroxetine can significantly increase the plasma levels of these drugs, raising the risk of serious side effects such as QT interval prolongation.

Clinically Significant Interactions

  • Serotonergic Drugs: Co-administration with other serotonergic agents (e.g., triptans, fentanyl, tramadol, St. John's wort, lithium, or buspirone) increases the risk of Serotonin Syndrome.
  • Bleeding Risk: Concurrent use with drugs that affect blood clotting, such as aspirin, NSAIDs, warfarin, and other anticoagulants, increases the risk of abnormal bleeding.
  • CYP2D6 Substrates: Paroxetine is a potent inhibitor of the CYP2D6 liver enzyme. This can lead to increased blood concentrations of drugs primarily metabolized by this enzyme (e.g., certain antiarrhythmics and antidepressants), potentially requiring a dosage reduction of the co-administered drug.
  • Tamoxifen: Concomitant use with paroxetine may reduce the efficacy of tamoxifen, an agent metabolized by CYP2D6, and an alternative antidepressant may be advised.

Mechanism of Action

Parexat is a small molecule classified mechanistically as a selective serotonin reuptake inhibitor (SSRI). Its primary biological target is the serotonin transporter (SERT, SLC6A4) located on the presynaptic neuronal membrane. Parexat functions as a non-competitive inhibitor of SERT, binding to the transporter protein and allosterically or orthosterically blocking the reuptake process of the neurotransmitter serotonin (5-hydroxytryptamine, 5-HT) from the synaptic cleft into the presynaptic neuron.

This molecular interaction results in an increase in the extracellular concentration of 5-HT within the synaptic space. The subsequent increase in 5-HT availability promotes enhanced and sustained engagement with both presynaptic and postsynaptic 5-HT receptors. The downstream intracellular consequence of chronic SERT inhibition is a gradual neuroadaptive change, including the desensitization and downregulation of specific presynaptic 5-HT autoreceptors, particularly the 5- HT1 A and 5- HT1 D subtypes. The overall system-level physiological consequence is the long-term modulation of serotonergic neurotransmission and signaling pathways within the central nervous system.

Dosage and Administration Information

How Parexat is Used: Administration Guidelines

Parexat (Paroxetine) is a prescription-only medication that is always administered orally in one of its available forms: immediate-release (IR) film-coated tablets, extended-release (ER) tablets, or oral suspension. The general principle of use is to initiate therapy at a low dose and adjust the quantity slowly over time.

Standard Dosing and Frequency

Administration for all approved indications is once daily, typically taken in the morning. The medication can be taken with or without food. Dosing is highly specific to the condition, but dosage increases are usually made in increments of 10 mg (IR) or 12.5 mg (ER) at intervals of at least 1 week.

Condition (IR Tablet) Usual Starting Dose Maximum Daily Dose
Major Depressive Disorder (MDD) 20 mg 50 mg
Obsessive-Compulsive Disorder (OCD) 20 mg 60 mg
Panic Disorder (PD) 10 mg 60 mg

Special Administration Requirements

Standard instructions require specific handling for certain formulations. Extended-release tablets must be swallowed whole and must not be crushed or chewed due to the requirement for controlled absorption. The oral suspension must be shaken well before each use. If a dose is missed, it is recommended that it should be omitted, and the next dose taken at the regularly scheduled time; a double dose must not be taken.

Population Adjustments

Initial and maximum dosage amounts are reduced for specific patient populations. For older adults and patients with severe renal or hepatic impairment, the starting dose is often halved (e.g., 10 mg IR daily) to account for altered drug clearance. Furthermore, treatment duration for conditions like depression typically requires continuation for at least six months following recovery. When discontinuing treatment, the dose must be tapered gradually over a period of weeks or months to follow standard clinical practices.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research Focus and Initial Investigations

Research has explored the drug's potential mechanism of action, which involves the reuptake of neurotransmitters. Studies have investigated the potential for the drug's mechanism to be associated with an effect on symptoms of major depression and anxiety. Early preclinical research evaluated the drug’s binding affinity and selectivity for transporter proteins.

Key Clinical Findings

Key Findings from Randomized Controlled Trials (RCTs):

Numerous studies have examined whether the drug affects mood scores. These trials typically compare the drug's effects to a placebo or to an active comparator.

  • One large-scale RCT reported changes in the Hamilton Depression Rating Scale (HAM-D) scores after treatment. The study was conducted over eight weeks and involved adults with a primary diagnosis of major depressive disorder.
  • Another RCT focused on generalized anxiety disorder and evaluated the drug's effects on the Hamilton Anxiety Rating Scale (HAM-A) scores over a 12-week period.

Long-Term Follow-Up and Maintenance Studies

Research on long-term outcomes has evaluated the drug's use over periods up to 12 months.

  • A follow-up study investigated outcomes, including the time to recurrence of symptoms, when treatment was continued for six months or more compared to discontinuation. The study collected data on the time to recurrence of major depressive episodes.
  • Comparative effectiveness research has evaluated the drug against older generations of antidepressants and other contemporary treatments. These studies typically use standard efficacy measures and compare reported adverse event profiles.

Pharmacokinetics and Specific Populations

Research has included elderly patients, examining pharmacokinetics and potential differences in reported adverse events compared to younger adult populations. Studies have also examined the drug’s use in individuals with a history of heart issues and monitored cardiovascular parameters. Studies have also explored the drug’s use in other conditions, such as chronic pain. Studies of medication adherence have explored its relationship with outcomes.

Key Studies & References NICE Guideline for the Management of Chronic Pain: Pharmacological Treatment Recommendations

Frequently Asked Questions (FAQ)

Common questions about Parexat (FAQ)

Q: Why is close monitoring needed when starting Parexat in younger adults?

Official regulatory warnings state that there is an increased risk of suicidal thoughts and behaviors documented in young adults (typically under 25) who start taking antidepressants. For this reason, close monitoring is required as specified in the official labeling, particularly during the initial months of therapy and following any dose changes.


Q: Why do some people feel agitated or restless when they start Parexat?

Regulatory documents report that some people may experience psychomotor restlessness, known clinically as Akathisia. This is an adverse reaction that involves a feeling of inner agitation or the inability to sit or stand still. It is most often reported to occur within the first few weeks after starting treatment with Parexat.


Q: Can Parexat cause sweating or heat intolerance?

Official product information lists increased sweating (diaphoresis) as a Common side effect. Heat intolerance is not explicitly listed, though sweating is reported as a Common adverse reaction.


Q: Can Parexat cause weight gain, and how common is that side effect?

According to official regulatory documents, weight gain has been reported as an adverse reaction in clinical trials, although it is not typically categorized as one of the most common effects. Weight loss has also been reported as an adverse reaction.


Q: What are the signs of Parexat withdrawal symptoms?

Stopping Parexat suddenly can lead to a condition known as discontinuation syndrome (withdrawal). Symptoms may include dizziness, headache, tiredness, numbness or tingling sensations, changes in mood, irritability, anxiety, and sleep disturbances.


Q: Does Parexat interact with common pain relievers like ibuprofen?

Official safety information advises caution when Parexat is used with drugs that affect blood clotting, such as NSAIDs (Non-Steroidal Anti-Inflammatory Drugs). Since ibuprofen is an NSAID, concurrent use may increase the risk of abnormal bleeding, and is listed as a combination to approach with caution.


Q: Can Parexat affect my sleep patterns, like making me drowsy or causing insomnia?

Official information lists both somnolence (drowsiness or feeling sleepy) and insomnia (difficulty sleeping) as Common adverse reactions. Both somnolence and insomnia are listed as Common adverse reactions in the official information.


Q: Is it true that Parexat can cause sexual side effects, and are they permanent?

Parexat is commonly associated with sexual dysfunction symptoms, such as decreased libido or problems achieving orgasm. While these symptoms typically resolve after the medication is stopped, official regulatory information has noted reports of long-lasting sexual dysfunction that persists after discontinuation.


Q: Can taking Parexat affect fertility or the ability to conceive?

Official product information indicates that in men, paroxetine may potentially reduce sperm quality, though the extent to which this affects fertility is unknown. For women, there is no consistent regulatory evidence suggesting a reduction in fertility.


Q: Is Parexat considered safe for pregnant or breastfeeding people (in general terms)?

Use during pregnancy, particularly the first trimester, is generally avoided due to a documented, small risk of fetal harm, such as cardiac defects. The drug also passes into breast milk. Use during these periods is conditional and requires a careful assessment of individual risks and benefits by a healthcare professional.


Q: What is the risk of serotonin syndrome with Parexat?

Official warnings state that Serotonin Syndrome is a known, potentially serious risk, especially if Parexat is combined with other serotonergic agents. Symptoms of this condition include changes in mental status, autonomic instability (such as heart rate and blood pressure fluctuations), and neuromuscular abnormalities.


Q: Is it typical to experience temporary nausea when starting Parexat?

Official reports indicate that Nausea is a Very Common adverse reaction, meaning it affects more than 1 in 10 people. Common side effects often appear early in treatment, and the onset and duration of common side effects can vary.


Q: How does the mechanism of Parexat help with OCD symptoms?

Parexat is officially indicated for the treatment of Obsessive-Compulsive Disorder (OCD). Its effectiveness is presumed to be related to its primary mechanism, which is the potentiation, or strengthening, of serotonergic activity (serotonin signaling) in the brain.


Q: Are there certain over-the-counter cold medicines to avoid while taking Parexat?

Caution is advised with any over-the-counter medicines that are also serotonergic agents, as combining them with Parexat increases the risk of Serotonin Syndrome. The use of such combinations is generally advised to be approached with caution.

How should Parexat be stored and disposed of?

How to Store and Dispose of Parexat?

The storage and disposal of Parexat (paroxetine) must adhere to the specific requirements detailed in official regulatory labeling to ensure product integrity and safety.


Storage Requirements

Parexat must be stored at controlled room temperature, typically between 20°C and 25°C. The container must be kept tightly closed and protected from excess heat, moisture, and light. To prevent accidental ingestion, all forms of this medication must be stored out of the sight and reach of children and pets.

Disposal Instructions

Unused or expired Parexat should ideally be disposed of using a drug take-back program. If this is not an option, the medication can be mixed with an undesirable substance (such as dirt or coffee grounds), sealed in a bag, and then placed in the household trash. The medication must not be flushed down a toilet or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Parexat found in:

A-Z Index: